Cohen & Steers Inc. (CNS)
NYSE: CNS
· Real-Time Price · USD
66.65
-0.66 (-0.98%)
At close: Sep 24, 2025, 3:59 PM
66.64
-0.02%
After-hours: Sep 24, 2025, 06:27 PM EDT
-0.98% (1D)
| Bid | 66.28 |
| Market Cap | 3.4B |
| Revenue (ttm) | 560.26M |
| Net Income (ttm) | 162.12M |
| EPS (ttm) | 3.15 |
| PE Ratio (ttm) | 21.16 |
| Forward PE | 19.91 |
| Analyst | Hold |
| Dividends | $3.04 |
| Ask | 70.46 |
| Volume | 191,351 |
| Avg. Volume (20D) | 273,680 |
| Open | 67.34 |
| Previous Close | 67.31 |
| Day's Range | 66.28 - 67.34 |
| 52-Week Range | 66.28 - 110.67 |
| Beta | 1.39 |
| Ex-Dividend Date | Aug 11, 2025 |
Analyst Forecast
According to 0 analyst ratings, the average rating for CNS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsCohen & Steers Inc. is scheduled to release its earnings on
Oct 15, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
5 months ago
+9.62%
Shares of capital market companies are trading hig...
Unlock content with
Pro Subscription
6 months ago
+2.6%
Shares of financial stocks are trading higher amid overall market strength on reports of potentially narrowed or targeted tariffs, which may be easing investor concerns.
23 hours ago · seekingalpha.com
MapLight Therapeutics Starts $100 Million IPO Effort For CNS TreatmentsMapLight Therapeutics is a clinical-stage biopharma focused on CNS disorders and has filed for a $100 million U.S. IPO to fund its pipeline. MPLT's lead drug, ML-07C-MA, targets schizophrenia and Alzh...
